Objective: To evaluate the differences in short- and mid-term outcomes for intramural hematoma in the type A distribution (TAIMH) and acute type A aortic dissection (ATAAD) patients treated at a single institution between 2000 and 2020 to provide insight into whether an emergent surgical treatment strategy for TAIMH is an acceptable treatment option.
Methods: Between January 2000 and December 2020, a total of 903 patients were treated for acute aortic syndrome at Stanford Hospital. Baseline characteristics, operative details, short-term postoperative outcomes, mid-term survival, and reoperation rates were examined for this cohort. Cardinality matching was used to control for baseline characteristics and presentation symptoms. Fine balance matching was used to control for cannulation strategy.
Results: A total of 187 TAIMH patients were treated surgically and 27 were managed medically. The ATAAD arm included 642 patients who underwent surgery and 47 who were managed nonoperatively. ATAAD operative patients were more commonly male and younger compared to the TAIMH operative patients; however, other baseline medical history was similar in the 2 arms. ATAAD patients presented with higher rates of malperfusion and aortic regurgitation. Cross-clamp and cardiopulmonary bypass times were longer in the ATAAD arm, and these patients underwent more root replacements. Short-term postoperative outcomes were similar in the 2 arms, and there was no significant difference in unadjusted long-term survival and freedom from reoperation. With cardinality matching for preoperative history and presentation symptoms, mid-term survival was better for TAIMH patients. With fine balance matching for cannulation strategy, there was no significant difference between the groups in mid-term survival or stroke.
Conclusions: In conclusion, a surgical management strategy for acute TAIMH results in excellent postoperative outcomes and supports an aggressive emergent operative strategy in aortic centers of excellence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883695 | PMC |
| http://dx.doi.org/10.1016/j.xjon.2024.09.033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adrenomedullin Inhibits the Efficacy of Combined Immunotherapy and Targeted Therapy in Biliary Tract Cancer by Disrupting Endothelial Cell Functions.
J Cell Mol Med
March 2025
Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University & Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
The global incidence of biliary tract cancer (BTC) is on the rise, presenting a substantial healthcare challenge. The integration of immune checkpoint inhibitors (ICIs) with molecularly targeted therapies is emerging as a strategy to enhance immune responses. However, the efficacy and underlying mechanisms of these treatments in BTC are still largely unexplored.
View Article and Find Full Text PDFComparison of Early Functional Recovery Following Triportal Robot-Assisted and Uniportal Video-Assisted Segmentectomy in Patients With Early-Stage Non-Small Cell Lung Cancer: A Propensity Score-Matched Analysis.
Thorac Cancer
March 2025
Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan, P. R. China.
Background: Robot-assisted thoracoscopic surgery (RATS) is more precise and flexible than video-assisted thoracoscopic surgery (VATS) for early-stage non-small cell lung cancer (NSCLC) treatment. This study compared the early postoperative functional recovery of patients who underwent triportal RATS with that of patients who underwent uniportal video-assisted thoracic surgery (UVATS) for segmentectomy.
Methods: This observational, prospective study included 172 patients with clinical stage I or II peripheral NSCLC who underwent RATS or UVATS segmentectomy.
Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study.
J Prev Alzheimers Dis
March 2025
Department of Pathophysiology School of Basic Medicine Key Laboratory of Education Ministry/Hubei Province of China for Neurological Disorders Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address:
Background: The swift rise in the prevalence of Alzheimer's disease (AD) alongside its significant societal and economic impact has created a pressing demand for effective interventions and treatments. However, there are no available treatments that can modify the progression of the disease.
Methods: Eight AD brain tissues datasets and three blood datasets were obtained.
Effect of optimal lesion preparation prior to implantation of a magnesium-based bioresorbable scaffold: 12-month results of the OPTIMIS study.
Cardiovasc Revasc Med
March 2025
Department of Cardiology, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark.
Background: Lumen reduction after bioresorbable scaffold implantation has been reported. This study aimed to assess the influence of pre-dilatation with a scoring balloon versus a standard non-compliant balloon prior to implanting a magnesium-based Magmaris bioresorbable scaffold (MgBRS) on lumen measurements using optical coherence tomography (OCT) and on clinical outcomes after 12 months.
Method: In the OPTIMIS-study (Optimal lesion preparation before implantation of a MgBRS in patients with coronary artery stenosis), patients were randomly assigned to pre-dilatation with a scoring balloon or a standard non-compliant balloon before MgBRS implantation.
T-cell Engagers in Prostate Cancer.
Eur Urol
March 2025
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address:
Owing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell-mediated killing of cancer cells by binding the CD3 receptor on T cells and a specific tumor antigen expressed on malignant cells, represent a promising therapeutic option. Multiple studies have explored the use of TCEs in previously treated patients with metastatic castration-resistant prostate cancer, and several ongoing trials are currently assessing novel TCEs either as single agents or in combinatorial regimens with molecules with a distinct mechanism of action (eg, androgen receptor pathway inhibitors and other immune-targeting agents).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!